RANBP9 suppresses tumor proliferation in colorectal cancer

Qin,Chunzhi; Zhang,Qin; Wu,Guangbin

doi:10.3892/ol.2019.10134

RANBP9 suppresses tumor proliferation in colorectal cancer

Authors:
- Chunzhi Qin
- Qin Zhang
- Guangbin Wu
View Affiliations

Affiliations: Department of General Surgery, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: March 8, 2019 https://doi.org/10.3892/ol.2019.10134
Pages: 4409-4416
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RAN binding protein 9 (RANBP9) is widely expressed in mammalian tissues, including osteosarcoma, lung, gastric and breast cancer tissues. However, currently, not much is known about the role of RANBP9 in colorectal cancer (CRC). In the present study, RANBP9 expression in CRC tissues and cell lines was measured by immunohistochemistry and western blotting, respectively. Subsequently, RANBP9‑short hairpin RNA (shRNA) and RANBP9 plasmids were constructed and transfected into HCT116 and HT29 cells. The effects of RANBP9 knockdown were assessed by Cell Counting kit‑8 and colony formation assays, and its effects on tumorigenicity in a nude mouse animal model were investigated. The effect of RANBP9‑shRNA on cell cycle progression was analyzed by flow cytometry, while cell cycle‑associated protein expression levels were examined by western blotting. Compared with in paired normal mucosa, RANBP9 was overexpressed in CRC tissues. Inhibition of RANBP9 in HCT116 and HT29 cells significantly promoted cell growth, colony formation and S phase transition, and increased tumorigenesis in vivo. Accordingly, RANBP9 overexpression inhibited cell growth and colony formation. Knockdown of RANBP9 was associated with upregulated cyclin A2 in the two cell lines. In conclusion, RANBP9 served an inhibitory role in CRC in vitro and in vivo. Therefore, RANBP9 may be considered a potential target for treatment of CRC.

View Figures

View References

1	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
2	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
3	Yokoyama N, Hayashi N, Seki T, Panté N, Ohba T, Nishii K, Kuma K, Hayashida T, Miyata T and Aebi U: A giant nucleopore protein that binds Ran/TC4. Nature. 376:184–188. 1995. View Article : Google Scholar : PubMed/NCBI
4	Murrin LC and Talbot JN: RanBPM, a scaffolding protein in the immune and nervous systems. J Neuroimmune Pharmacol. 2:290–295. 2007. View Article : Google Scholar : PubMed/NCBI
5	Salemi LM, Loureiro SO and Schild-Poulter C: Characterization of RanBPM molecular determinants that control its subcellular localization. PLoS One. 10:e01176552015. View Article : Google Scholar : PubMed/NCBI
6	Wang H, Lewsadder M, Dorn E, Xu S and Lakshmana MK: RanBP9 overexpression reduces dendritic arbor and spine density. Neuroscience. 265:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wang R, Palavicini JP, Wang H, Maiti P, Bianchi E, Xu S, Lloyd BN, Dawson-Scully K, Kang DE and Lakshmana MK: RanBP9 overexpression accelerates loss of dendritic spines in a mouse model of Alzheimer's disease. Neurobiol Dis. 69:169–179. 2014. View Article : Google Scholar : PubMed/NCBI
8	Valiyaveettil M, Bentley AA, Gursahaney P, Hussien R, Chakravarti R, Kureishy N, Prag S and Adams JC: Novel role of the muskelin-RanBP9 complex as a nucleocytoplasmic mediator of cell morphology regulation. J Cell Biol. 182:727–739. 2008. View Article : Google Scholar : PubMed/NCBI
9	Rex EB, Rankin ML, Yang Y, Lu Q, Gerfen CR, Jose PA and Sibley DR: Identification of RanBP 9/10 as interacting partners for protein kinase C (PKC) gamma/delta and the D1 dopamine receptor: Regulation of PKC-mediated receptor phosphorylation. Mol Pharmacol. 78:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zhao Z, Cheng S, Zabkiewicz C, Chen J, Zhang L, Ye L and Jiang WG: Reduced expression of ranBPM is associated with poorer survival from lung cancer and increased proliferation and invasion of lung cancer cells in vitro. Anticancer Res. 37:4389–4397. 2017.PubMed/NCBI
11	Shao S, Sun PH, Satherley LK, Gao X, Ji KE, Feng YI, Jia Y, Ji J, Jiang WG and Ye L: Reduced ranBPM expression is associated with distant metastasis in gastric cancer and chemoresistance. Anticancer Res. 36:1295–1303. 2016.PubMed/NCBI
12	Dai H, Lv YF, Yan GN, Meng G, Zhang X and Guo QN: RanBP9/TSSC3 complex cooperates to suppress anoikis resistance and metastasis via inhibiting Src-mediated Akt signaling in osteosarcoma. Cell Death Dis. 7:e25722016. View Article : Google Scholar : PubMed/NCBI
13	Zhu LL, Wang CH, Yang HP and Shu WH: Expression of cartilage antitumor component RanBP9 in osteosarcoma. J Biol Regul Homeost Agents. 30:103–110. 2016.PubMed/NCBI
14	Emberley ED, Gietz RD, Campbell JD, HayGlass KT, Murphy LC and Watson PH: RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer. 2:282002. View Article : Google Scholar : PubMed/NCBI
15	Qin C, Ren L, Ji M, Lv S, Wei Y, Zhu D, Lin Q, Xu P, Chang W and Xu J: CDKL1 promotes tumor proliferation and invasion in colorectal cancer. Onco Targets Ther. 10:1613–1624. 2017. View Article : Google Scholar : PubMed/NCBI
16	Wang H, Yang R, Zhong L, Zhu XY, Ma PP, Yang XQ, Jiang KL and Liu BZ: Location of NLS-RARalpha protein in NB4 cell and nude mice. Oncol Lett. 13:2045–2052. 2017. View Article : Google Scholar : PubMed/NCBI
17	Meng X, Franklin DA, Dong J and Zhang Y: MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhang MF, Zhang ZY, Fu J, Yang YF and Yun JP: Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med. 7:1102009. View Article : Google Scholar : PubMed/NCBI
19	Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W and Behrens J: Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 22:1184–1193. 2002. View Article : Google Scholar : PubMed/NCBI
20	Malumbres M: Cyclin-dependent kinases. Genome Biol. 15:1222014. View Article : Google Scholar : PubMed/NCBI
21	Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
22	Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA and Fuchs CS: A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 15:4431–4438. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhao P, Hu YC and Talbot IC: Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol. 9:2202–2206. 2003. View Article : Google Scholar : PubMed/NCBI
24	Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK and Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 3:1427–1438. 2004.PubMed/NCBI
25	Aklilu M, Kindler HL, Donehower RC, Mani S and Vokes EE: Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol. 14:1270–1273. 2003. View Article : Google Scholar : PubMed/NCBI
26	Motwani M, Rizzo C, Sirotnak F, She Y and Schwartz GK: Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther. 2:549–555. 2003.PubMed/NCBI
27	Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326. 2002. View Article : Google Scholar : PubMed/NCBI
28	Zindy F, Lamas E, Chenivesse X, Sobczak J, Wang J, Fesquet D, Henglein B and Bréchot C: Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun. 182:1144–1154. 1992. View Article : Google Scholar : PubMed/NCBI
29	Bloom J and Cross FR: Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 8:149–160. 2007. View Article : Google Scholar : PubMed/NCBI
30	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
31	Lakshmana MK, Chung JY, Wickramarachchi S, Tak E, Bianchi E, Koo EH and Kang DE: A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J. 24:119–127. 2010. View Article : Google Scholar : PubMed/NCBI
32	Brannetti B and Helmer-Citterich M: iSPOT: A web tool to infer the interaction specificity of families of protein modules. Nucleic Acids Res. 31:3709–3711. 2003. View Article : Google Scholar : PubMed/NCBI
33	Wang D, Li Z, Messing EM and Wu G: The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. J Biol Chem. 280:16393–16401. 2005. View Article : Google Scholar : PubMed/NCBI
34	Woo JA, Roh SE, Lakshmana MK and Kang DE: Pivotal role of RanBP9 in integrin-dependent focal adhesion signaling and assembly. FASEB J. 26:1672–1681. 2012. View Article : Google Scholar : PubMed/NCBI